Novartis invites scrutiny of effort to improve access to medicine<\/a><\/p>\n Effect of Novartis Access on availability and price of non-communicable disease medicines in Kenya: a cluster-randomised controlled trial\u00a0<\/span><\/a><\/p>\n Lancet Global Health Commentary on Article<\/a><\/p>\n Lancet Global Health Editorial on Article<\/a><\/p>\n Boston University Press Release on Article\u00a0<\/a><\/p>\n East African Medical Journal<\/p>\n PLoS One<\/p>\n Access to Asthma Medicines at the Household Level in Eight Counties of Kenya<\/a><\/p>\n International Journal of Tuberculosis and Lung Disease<\/p>\n Access to Diabetes Medicines at the Household Level in Eight Counties of Kenya<\/a><\/p>\n Journal of Diabetology<\/p>\n Access to Medicines for Asthma, Diabetes and Hypertension in Eight Counties of Kenya<\/a><\/p>\n Tropical Medicine and International Health<\/p>\n Access to Antihypertensive Medicines at the Household Level in Eight Counties of Kenya<\/a><\/p>\n Global Heart<\/p>\n We reviewed the initiatives of twenty-one research-based global biopharmaceutical companies to assess their strategies for improving access and the quality of evidence on the impact of their initiatives.<\/span><\/p>\n Industry-Led Access-To-Medicines Initiatives in Low- and Middle- Income Countries: Strategies and Evidence<\/a><\/p>\n Health Affairs<\/p>\n BMJ Open: Study protocol for a cluster-randomised controlled trial of an NCD access to medicines initiative: evaluation of <\/span>Novartis Access<\/em> in Kenya<\/span><\/a>\u00a0(Full Protocol)<\/p>\n ClinicalTrials.gov: Evaluation of Novartis Access; a Non-communicable Disease (NCD) Access Initiative<\/a> (Protocol Summary)<\/p>\n Dr. Richard Laing’s presentation on the Evaluation of Novartis Access at the World Health Assembly in Geneva, Switzerland, on May 25th, 2016 (Full<\/a>)<\/p>\n Dr. Richard Laing’s presentation on the Evaluation of Novartis Access at the Ecumenical Pharmaceutical Network forum in T\u00fcbingen, Germany, on May 19th, 2016 (Abbreviated<\/a>)<\/p>\n A report summarizing meetings with County Health Officials in Kenya, March 10th – 13th 2020\u00a0\u00a0<\/a><\/p>\n Availability and prices of medicines for non-communicable diseases at health facilities and retail drug outlets in Kenya: a cross-sectional survey in eight counties<\/a><\/p>\n Phone-based monitoring to e<\/a>valuate health policies and program implementation in Kenya<\/a><\/p>\n Associate between risk factors and mortality in patients with non-communicable diseases in eight Kenyan counties: an observational cohort study<\/a><\/p>\n
\nEffect of Novartis Access on Availability and Price of Medicines in Kenya<\/h4>\n
\nPrevalence and Treatment of Chronic Diseases\u00a0in Kenya<\/h4>\n
\nPerceptions on Access to Medicines for NCDs<\/h4>\n
\nEquity in Access to Non-Communicable Disease Medicines<\/h4>\n
\nBMJ Global Health<\/div>\n
\nAccess to Asthma Medicines<\/h4>\n
\nAccess to Diabetes Medicines<\/h4>\n
\nAccess to Asthma, Diabetes and Hypertension Medicines<\/h4>\n
\nAccess to Antihypertensive Medicines<\/h4>\n
\nStrategies for Improving Access and the Quality of Evidence<\/h4>\n
\nProtocol<\/h4>\n
\nPresentations<\/h4>\n
\nCounty Meetings Report<\/h4>\n
\nAvailability and Price of NCD medicines at Health Facilities<\/h4>\n
\nPhone-based Monitoring<\/h4>\n
\nAssociation between NCD Risk Factors and Mortality<\/h4>\n
\nCoping with access barriers to NCD medicines<\/h4>\n